The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Does imetelstat provide transfusion independence in lower-risk MDS?

During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Uwe Platzbecker, Leipzig University Hospital, Leipzig, DE. We asked: Does imetelstat provide transfusion independence in lower-risk MDS?

Does imetelstat provide transfusion independence in lower-risk MDS?

Patients with lower-risk MDS are predominantly affected by anemia and require regular red blood cell transfusions. Currently, there are no treatment options for patients with lower-risk MDS other than enrollment into clinical trials. Here, Uwe Platzbecker discusses the phase II study evaluating the first-in-class telomerase inhibitor, imetelstat, for the treatment of patients with lower-risk MDS. Imetelstat has demonstrated promising disease-modifying activity in this set of patients.

Share: